3M India Limited (3MINDIA) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

3M India, the Bengaluru-listed arm of 3M Company, USA, spans Safety & Industrial, Transportation & Electronics, Health Care and Consumer segments, and comes into this quarter on a streak of five consecutive quarters of double-digit YoY sales growth. The print will speak to whether that streak extends to a sixth quarter even as the rupee's depreciation and elevated input-cost inflation keep squeezing underlying profitability.

3M India Limited Q2 Results Date and Time

The board of 3M India meets on November 06, 2026 to consider and approve the unaudited financial results for the quarter ended September 30, 2026, under Reg. 29(1)(a) of SEBI (LODR). The trading window remained closed from October 1 to November 8, 2026 (both days inclusive) under the SEBI Prohibition of Insider Trading Regulations.

At the 39th AGM held on August 26, 2026, shareholders approved a total FY26 dividend of Rs. 506 per share, comprising a final dividend of Rs. 160 and a special dividend of Rs. 346. All 7 resolutions at the AGM were passed with more than 99.8% majorities, with the dividend declaration itself approved at a 99.993% vote share.

What to expect from 3M India Limited's Q2 FY27 results

The central question for Q2 FY27 is whether 3M India can extend its double-digit YoY sales-growth streak to a sixth consecutive quarter — Q1 FY27 grew 19.0% with all four segments up double digits (Safety & Industrial +23.0%, Health Care +23.5%, Transportation & Electronics +14.4%, Consumer +13.4%) — while underlying profitability remains under pressure.

The rupee, which management said was the primary driver of Q1's YoY decline in profitability excluding exceptional items, stayed pinned in the mid-94s to high-95s against the US dollar through the quarter (averaging 95.47/USD in August and touching 95.92 on September 15), so the FX headwind on related-party imports persisted rather than reversed.

Input costs add a second pressure: WPI manufactured-product inflation hit a series high of 8.37% in August with fuel and power above 22%, after Q1 FY27 material cost had already surged 472 bps to 61.48% of revenue and EBITDA margin compressed roughly 392 bps YoY to about 17.5%.

Demand proxies were broadly supportive for roughly two-thirds of the book — HSBC Manufacturing PMI rebounded to 55.1 in September after August's five-year low of 52.8, IIP manufacturing grew 9.0% in August, and SIAM reported Q2 PV sales of 1.36 mn units, up 30.7% YoY — though Consumer (about 11% of mix) faces a soft FMCG volume backdrop.

There is no quantified guidance to score against; the qualitative bar is management's stated stance that it 'remains optimistic' on India's growth and company prospects despite short-term volatility, trade protectionism and tariffs, and the call will likely test how that tone squares with 19%-type revenue growth alongside falling underlying profit.

Key Things To Watch

Guidance scorecard — open-ended strategic pillars: The company gives no quantified guidance (the Q3 FY25-26 deck states nothing should be construed as a forecast), so the pillars are qualitative checkpoints.

• Commercial Excellence initiatives — open-ended guidance — listen for any new quantification on pipeline building and spec-in wins at key customers
• Local R&D Capability (For-India products, global NPI leverage) and Local Supply Chain (outsourcing, capacity expansion and new manufacturing lines) — open-ended guidance, with the Ranjangaon expansion area the visible project
• Whether management's stated optimism despite short-term volatility, trade protectionism and tariffs survives Q2

Growth streak and EBITDA margin bridge

• Whether double-digit YoY sales growth extends to a 6th consecutive quarter (Q1 FY27 was the 5th, at 19.0%), and whether segment breadth holds or narrows
• EBITDA trajectory after Rs. 250 Cr in Q1 FY27 (down 2.7% YoY and 7.3% QoQ vs Rs. 269 Cr in Jan-Mar 2026) — quantification of the INR impact (rupee at ~95-96/USD through the quarter) versus pricing/mix pass-through
• INR depreciation impact on profitability excluding exceptional items, and whether reported EBITDA includes exceptional items

One-offs, Health Care transition and governance

• Recognition and timing of the US$13 million one-time Thermo Fisher compensation (board-approved Oct 26, 2026) under the amended Health Care Distribution Agreement/LMRA in a segment that was about 20% of FY26 mix
• LMRA amendment execution due within 30 calendar days of the Oct 26, 2026 board approval, and the Distribution Agreement now running 7 years from execution for continuing products
• H2 lapping of the Rs. 73.13 Cr Pimpri land-sale gain (consideration Rs. 82.00 Cr, deed executed Jun 29, 2026) that flattered Q1 PAT growth of +31.2% while PBT before exceptional items fell 4.3% YoY; Ms. Kong Sau Wai Elizabeth's resignation as director takes effect Nov 6, 2026 — the results date — with no successor disclosed